Abstract Library

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4355 Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,